Adaptimmune Therapeutics plc (473A) — Financial Flexibility Index
Adaptimmune Therapeutics plc (473A) has a Financial Flexibility Index of -0.17x as of June 2025. Free cash flow of €-34.70 Million (operating CF €-34.78 Million minus capex €75.00K) represents 0% of total liabilities (€201.59 Million). Check 473A strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Adaptimmune Therapeutics plc Financial Flexibility Index (2016–2024)
Historical Financial Flexibility Index trend for Adaptimmune Therapeutics plc across 9 annual periods. See Adaptimmune Therapeutics plc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Adaptimmune Therapeutics plc (2016–2024)
Year-by-year free cash flow to debt coverage for Adaptimmune Therapeutics plc. For the full company profile including market capitalisation, see Adaptimmune Therapeutics plc market cap and net worth.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.30x | €-70.49 Million | €-73.21 Million | €234.11 Million | ▲ +46.2% |
| 2023 | -0.56x | €-136.00 Million | €-140.88 Million | €243.10 Million | ▼ -23.1% |
| 2022 | -0.45x | €-112.27 Million | €-141.77 Million | €247.04 Million | ▼ -720.6% |
| 2021 | 0.07x | €19.30 Million | €10.73 Million | €263.58 Million | ▲ +115.7% |
| 2020 | -0.47x | €-51.25 Million | €-53.59 Million | €109.92 Million | ▲ +75.7% |
| 2019 | -1.92x | €-110.92 Million | €-112.51 Million | €57.91 Million | ▲ +43.1% |
| 2018 | -3.37x | €-100.48 Million | €-104.39 Million | €29.85 Million | ▼ -786.7% |
| 2017 | -0.38x | €-29.67 Million | €-54.31 Million | €78.16 Million | ▲ +26.6% |
| 2016 | -0.52x | €-35.38 Million | €-48.17 Million | €68.37 Million | — |